NCT07287995: A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 428 planned
- Started
- 5 Feb 2026
- Primary completion
- 30 Jun 2029
- Arms
- ASP2998 Dose Escalation, ASP2998 Dose Expansion, ASP2998 Monotherapy Dose Escalation (Tumor Specific), ASP2998 Monotherapy Dose Expansion (Tumor Specific)
- Results
- None posted
- 17 Dec 2025: Trial registered
- 5 Feb 2026: Trial started